{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-25-098992","form_type":"8-K","ticker":"BTAI","cik":"0001720893","company_name":"BioXcel Therapeutics, Inc.","filed_at":"2025-10-14T23:59:59+00:00","discovered_at":"2026-05-14T18:02:40.251032+00:00","generated_at":"2026-05-17T03:55:20.040890+00:00","sec_items":["8.01"],"event_type":"regulatory","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"BioXcel Therapeutics reports strong correlation between clinician & caregiver agitation scales; sNDA planned Q1 2026","bullets":["Correlation study (N=33) shows ρ=0.89 (patient) and ρ=0.88 (informant) between PEC and mCGI-S scales, p<0.0001.","No serious adverse events; safety profile consistent with IGALMI label.","Results to be included in sNDA submission for BXCL501 planned for Q1 2026.","mCGI-S scale developed with FDA for at-home efficacy assessment of acute agitation."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-25-098992","json":"https://secwatch.observer/filing/0001104659-25-098992.json","markdown":"https://secwatch.observer/filing/0001104659-25-098992.md","text":"https://secwatch.observer/filing/0001104659-25-098992.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1720893/000110465925098992/0001104659-25-098992-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1720893/000110465925098992/tm2528636d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T03:55:20.040890+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}